LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference

Rhea-AI Summary

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that CEO Stephen Hurly will present at the 2021 Jefferies Virtual Healthcare Conference on June 1, 2021, at 11:30 a.m. ET. The presentation will be available via webcast on the company's website. LAVA is a biotechnology firm focusing on bispecific gamma-delta T cell engagers aimed at treating solid tumors and hematological malignancies. The company plans to release clinical data for LAVA-051 by mid-2022 and initiate a clinical study for LAVA-1207 in prostate cancer in late 2021.

UTRECHT, The Netherlands and PHILADELPHIA, May 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:30 a.m. ET.

The presentation will be webcast and can be accessed from the investor relations section of the company's website at www.lavatherapeutics.com.

About LAVA

LAVA Therapeutics N.V. is a clinical stage biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematological malignancies based on its proprietary platform. The company’s innovative approach utilizes bispecific antibodies engineered to selectively kill cancer cells and induce gamma-delta T cell-mediated immunity through activation of Vγ9Vδ2 T cells upon cross-linking to tumor associated antigens. A Phase 1/2a clinical study evaluating LAVA-051 in patients with certain hematologic malignancies is anticipated to generate top line clinical data in the first half of 2022. The Company expects to initiate a Phase 1/2a clinical study to evaluate LAVA-1207 in patients with prostate cancer in the second half of 2021. For more information, please visit www.lavatherapeutics.com.

Contact
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

FAQ

When will LAVA Therapeutics present at the Jefferies Virtual Healthcare Conference?

LAVA Therapeutics will present on June 1, 2021, at 11:30 a.m. ET.

How can I access LAVA Therapeutics' conference presentation?

The presentation can be accessed via webcast on the investor relations section of LAVA Therapeutics' website.

What is the focus of LAVA Therapeutics?

LAVA Therapeutics focuses on bispecific gamma-delta T cell engagers for cancer therapy.

What clinical studies is LAVA Therapeutics planning?

LAVA plans to generate data for LAVA-051 by mid-2022 and start a study for LAVA-1207 in prostate cancer in the second half of 2021.

What is the stock symbol for LAVA Therapeutics?

The stock symbol for LAVA Therapeutics is LVTX.